



## MassHealth Supplemental Rebate/ Preferred Drug List

This page lists those drugs for which MassHealth has entered into a supplemental rebate agreement with drug manufacturers, allowing MassHealth the ability to provide medications at the lowest possible costs.

The items are listed alphabetically by therapeutic class, then by the name of the drug or drug ingredients. Please note that MassHealth may still require prior authorization for clinical reasons. Drugs that require additional prior authorization requirements are noted with PA on this list.

In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing a non-preferred drug within a therapeutic class.

### **Analgesic Agents:**

[See Therapeutic Class Table 8 on the MassHealth Drug List for Opioids and Analgesics.](#)

- Journavx (suzetrigine) – **PA > 29 units/60 days**

### **Anticoagulant Agent:**

[See Therapeutic Class Table 58 on the MassHealth Drug List for Anticoagulants and Antiplatelet Agents.](#)

- Eliquis (apixaban tablet)

### **Antidepressant Agents:**

[See Therapeutic Class Table 17 on the MassHealth Drug List for Antidepressant Agents.](#)

- Zuruvae (zuranolone) – **PA**

### **Antidiabetic Agents:**

[See Therapeutic Class Table 26 on the MassHealth Drug List for Antidiabetic Agents.](#)

- Glyxambi (empagliflozin/linagliptin)
- Jardiance (empagliflozin)
- Ozempic (semaglutide injection) – **PA**
- Synjardy (empagliflozin/metformin)
- Synjardy XR (empagliflozin/metformin extended-release)

### **Anti-Hemophilia Agents:**

[See Therapeutic Class Table 80 on the MassHealth Drug List for Anti-Hemophilia Agents.](#)

- Benefix (factor IX human recombinant)
- Hemlibra (emicizumab-kxwh)
- Jivi (antihemophilic factor, recombinant pegylated-aucl)

- Kovaltry (antihemophilic factor, recombinant)
- Xyntha (antihemophilic factor, recombinant)

### **Anti-Hypoglycemic Agent:**

[See Therapeutic Class Table 78 on the MassHealth Drug List for Diabetes Emergency Treatment Agents.](#)

- Baqsimi (glucagon nasal powder)

### **Anti-Obesity Agent:**

[See Therapeutic Class Table 81 on the MassHealth Drug List for Anti-Obesity Agents.](#)

- Wegovy (semaglutide injection) – **PA**
- Zepbound (tirzepatide) – **PA**

### **Antiretroviral/HIV Agents:**

[See Therapeutic Class Table 38 on the MassHealth Drug List for Antiretroviral/HIV Agents.](#)

- Apretude (cabotegravir injection)
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- Cabenuva (cabotegravir/rilpivirine)
- Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)
- Descovy (emtricitabine/tenofovir alafenamide)
- Dovato (dolutegravir/lamivudine)
- Juluca (dolutegravir/rilpivirine)
- Norvir (ritonavir tablet)
- Pifeltro (doravirine)
- Prezcobix (darunavir/cobicistat)
- Rukobia (fostemsavir) – **PA**
- Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)
- Triumeq (abacavir/dolutegravir/lamivudine)
- Yeztugo (lenacapavir)

### **Anti-TNF Agents:**

[See Therapeutic Class Table 5 on the MassHealth Drug List for Anti-TNF Agents.](#)

- adalimumab-adaz, unbranded – **PA**
- Enbrel (etanercept) – **PA**
- Hadlima (adalimumab-bwwd) – **PA**

### **Antipsychotic Agent oral Second Generation (Atypical):**

[See Therapeutic Class Table 24 on the MassHealth Drug List for oral Second Generation \(Atypical\) Antipsychotic Agents.](#)

- Caplyta (lumateperone) – **PA**
- Rexulti (brexipiprazole) – **PA**
- Vraylar (cariprazine) – **PA**

## **Asthma and Allergy Agent:**

[See Therapeutic Class Table 64 on the MassHealth Drug List for Asthma/Allergy Monoclonal Antibodies.](#)

- Dupixent (dupilumab) – **PA**

## **Calcitonin Gene-Related Peptide Inhibitors:**

[See Therapeutic Class Table 14 on the MassHealth Drug List for Calcitonin Gene-Related Peptide Inhibitors.](#)

- Ajoovy (fremanezumab-vfrm) – **PA**
- Emgality (galcanezumab-gnlm) – **PA**
- Nurtec (rimegepant) – **PA**
- Qulipta (atogepant) – **PA**
- Ubrelvy (ubrogepant) – **PA**

## **Cerebral Stimulant:**

[See Therapeutic Class Table 31 on the MassHealth Drug List for Cerebral Stimulants.](#)

- Adderall XR (amphetamine salts extended-release) – **PA < 3 years or ≥ 21 years and PA > 2 units/day**
- Vyvanse (lisdexamfetamine) – **PA < 3 years or ≥ 21 years and PA > 2 units/day**

## **COVID-19 Agents:**

[See Therapeutic Class Table 72 on the MassHealth Drug List for COVID-19 Related Medications.](#)

- Paxlovid (nirmatrelvir/ritonavir 150-100 mg) – **PA < 12 years and PA > 20 units/claim**
- Paxlovid (nirmatrelvir/ritonavir 300-100 mg) – **PA < 12 years and PA > 30 units/claim**
- Paxlovid (nirmatrelvir/ritonavir 300/150-100 mg) – **PA < 12 years and > 11 units/claim**

## **Cystic Fibrosis Agents:**

[See Therapeutic Class Table 21 on the MassHealth Drug List for Cystic Fibrosis Agents.](#)

- Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) – **PA**
- Kalydeco (ivacaftor) – **PA**
- Orkambi (lumacaftor/ivacaftor) – **PA**
- Symdeko (tezacaftor/ivacaftor) – **PA**
- Trikafta (elexacaftor/tezacaftor/ivacaftor) – **PA**

## **Dermatologic Agents:**

[See Therapeutic Class Table 63 on the MassHealth Drug List for Dermatologic Agents.](#)

- Ycanth (cantharidin) – **PA**

## **Drug and Alcohol Cessation Agents:**

[See Therapeutic Class Table 36 on the MassHealth Drug List for Drug and Alcohol Cessation Agents.](#)

- Brixadi (buprenorphine extended-release injection)
- Sublocade (buprenorphine extended-release injection)

- Suboxone (buprenorphine/naloxone film) – **PA > 32 mg/day**
- Vivitrol (naltrexone injection)

### **Enzyme and Metabolic Disorder Therapy:**

[See Therapeutic Class Table 65 on the MassHealth Drug List for Enzyme and Metabolic Disorder Therapies.](#)

- Carbaglu (carglumic acid) – **PA**

### **Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist:**

[See Therapeutic Class Table 26 on the MassHealth Drug List for GLP-1 Receptor Agonists.](#)

- Trulicity (dulaglutide) – **PA**

### **Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon Like Peptide (GLP)-1 Agonist**

[See Therapeutic Class Table 26 on the MassHealth Drug List for GIP and GLP-1 Receptor Agonists.](#)

- Mounjaro (tirzepatide) – **PA**

### **Gonadotropin-Releasing Hormone Analogs:**

[See Therapeutic Class Table 2 on the MassHealth Drug List for Gonadotropin-Releasing Hormone Analogs.](#)

- Fensolvi (leuprolide) – **PA**

### **Growth Hormone:**

[See Therapeutic Class Table 9 on the MassHealth Drug List for Growth Hormones.](#)

- Genotropin (somatropin) – **PA**
- Ngenla (somatrogon-ghla) – **PA**
- Sogroya (somapacitan-beco) – **PA**

### **Hepatitis Antivirals:**

[See Therapeutic Class Table 44 on the MassHealth Drug List for Hepatitis Antiviral Agents.](#)

- Iedipasvir/sofosbuvir\* – **PA**
- Mavyret (glecaprevir/pibrentasvir) – **PA**
- sofosbuvir/velpatasvir\* – **PA**
- Vemlidy (tenofovir alafenamide)

\* Please note, pediatric dosing formulations of Brand name Epclusa and Harvoni are preferred. For all other strengths, generics are preferred.

### **Inhaled Respiratory Agent:**

[See Therapeutic Class Table 23 on the MassHealth Drug List for Inhaled Respiratory Agents.](#)

- Symbicort (budesonide/formoterol)

### **Interleukin Antagonists:**

[See Therapeutic Class Table 5 on the MassHealth Drug List for Interleukin Antagonist.](#)

- Adbry (tralokinumab-ldrm) – **PA**
- Ebglyss (lebrikizumab-lbkz) – **PA**
- Imuldosa (ustekinumab-srlf prefilled syringe) – **PA**
- Imuldosa (ustekinumab-srlf vial) – **PA**
- Omvoh (mirikizumab-mrkz auto-injection, prefilled syringe) – **PA**
- Pyzchiva (ustekinumab-ttwe 130 mg/26 mL vial) – **PA**
- Pyzchiva (ustekinumab-ttwe prefilled syringe, 45 mg/0.5 mL vial) – **PA**
- Skyrizi (risankizumab-rzaa auto-injection, on-body injector, prefilled syringe) – **PA**
- Skyrizi (risankizumab-rzaa vial) – **PA**
- Taltz (ixekizumab) – **PA**

### **Long-Acting Aripiprazole Agents:**

[See Therapeutic Class Table 24 on the MassHealth Drug List for Long-Acting Aripiprazole and Second Generation \(Atypical\) Antipsychotic Agents.](#)

- Aristada (aripiprazole lauroxil 441 mg, 662 mg, 882 mg) – **PA < 10 years and PA > 1 injection/28 days**
- Aristada (aripiprazole lauroxil 1,064 mg) – **PA < 10 years and PA > 1 injection/56 days**
- Aristada Initio (aripiprazole lauroxil 675 mg) – **PA < 10 years and PA > 1 injection/28 days**

### **Long-Acting Risperidone Agents:**

[See Therapeutic Class Table 24 on the MassHealth Drug List for Long-Acting Risperidone and Second Generation \(Atypical\) Antipsychotic Agents.](#)

- Perseris (risperidone 90 mg, 120 mg extended-release subcutaneous injection) – **PA < 10 years and PA > 1 injection/28 days**
- Uzedy (risperidone 50 mg, 75 mg, 100 mg, 125 mg extended-release subcutaneous injection) – **PA < 10 years and PA > 1 injection/28 days**
- Uzedy (risperidone 150 mg, 200 mg, 250 mg extended-release subcutaneous injection) – **PA < 10 years and PA > 1 injection/56 days**

### **Long-Acting Paliperidone Agents:**

[See Therapeutic Class Table 24 on the MassHealth Drug List for Long-Acting Paliperidone and Second Generation \(Atypical\) Antipsychotic Agents.](#)

- Erzofri (paliperidone extended-release 1-month injection) – **PA < 10 years and PA > 1 injection/28 days**
- Invega Hafyera (paliperidone extended-release 6-month injection) – **PA < 10 years and PA > 1 injection/168 days**
- Invega Sustenna (paliperidone extended-release 1-month injection) – **PA < 10 years, PA > 2 injections/28 days within the first 28 days of therapy and PA > 1 injection/28 days after 28 days of therapy**
- Invega Trinza (paliperidone extended-release 3-month injection) – **PA < 10 years and PA > 1 injection/84 days**

### **Oncology Agents:**

[See Therapeutic Class Table 57 on the MassHealth Drug List for Oncology Agents.](#)

- Ibrance (palbociclib) – **PA**

### **Opioid Reversal Agent:**

[See Therapeutic Class Table 36 on the MassHealth Drug List for Drug and Alcohol Cessation Agents.](#)

- Kloxxado (naloxone 8 mg nasal spray)

### **Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Gene Therapy:**

[See Therapeutic Class Table 45 on the MassHealth Drug List for Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Agents Gene Therapies.](#)

- Casgevy (exagamglogene autotemcel) – **PA**

### **Small Interfering RNA Agents:**

[See Therapeutic Class Table 72 on the MassHealth Drug List for Agents not Otherwise Classified.](#)

- Givlaari (givosiran) – **PA**
- Onpattro (patisiran) – **PA**
- Oxlummo (lumasiran) – **PA**

### **Spinal Muscular Atrophy Agent:**

[See Therapeutic Class Table 76 on the MassHealth Drug List for Spinal Muscular Atrophy Agents.](#)

- Zolgensma (onasemnogene abeparvovec-xioi) – **PA**

### **Topical Immune Suppressant:**

[See Therapeutic Class Table 42 on the MassHealth Drug List for Immune Suppressants – Topical.](#)

- Eucrisa (crisaborole) – **PA**
- Opzelura (ruxolitinib cream) – **PA**
- Zoryve (roflumilast cream, foam) – **PA**